Tower Bridge, London, at dusk — from Technomark's own photography

Life-Science Investment Group · Est. London 1987

Capital that shares the risk of clinical development.

Since 1987, Technomark has backed life-science companies as investors, strategists, and partners — co-funding Phase I–IV clinical programs from London and Philadelphia.

Start a Conversation Fund I Track Record

1987 Est. London

7 of 8 Fund I exits

Phase I–IV Co-funded programs

01 · Mandate

An investment group with a life‑science focus.

Technomark invests only in programs where its development and regulatory expertise can change the outcome. As long-term investors, we invest and co-fund the clinical development of our portfolio companies in a hands-on manner.

Our global presence allows us to provide turn-key solutions for clinical development programs, primarily in the US and Europe and in other selective regions, as part of our co-development investment model.

Sector: Therapeutics (biologics, NCE, orphan), med‑tech, device & diagnostic
Stage: Phase I–IV clinical trials
Investment: Seed to Series C
Return: Equity, downstream royalties, milestone payments
Geography: UK & rest of EU, US, Israel

02 · The Model

Co-development, since 2009.

Under our co-funding model we share the risk and the cost of clinical studies in exchange for downstream remuneration — which lets us be more involved than a line on a cap table.

i.
Co-fund

We share the cost and risk of Phase I–IV clinical studies with our portfolio companies, structured around equity, royalties, or milestones.
ii.
Co-develop

We act as lead or co-lead investor, structuring the round and shaping development and regulatory strategy alongside management.
iii.
Stay close

Through a hand-selected network of boutique clinical CROs, we work as investors, strategists, and partners — or first-hand observers.

03 · Track Record

Fund I: eight investments, seven exits.

Established in 2000 to invest in early-stage life-science companies across the UK and continental Europe. In each investment, Technomark acted as lead or co-lead investor.

Amedis Pharmaceuticalsacquired by Takeda
Arakisacquired by Sosei
Biovexacquired by Amgen
Paradigm Therapeuticsacquired by Takeda
Proteomacquired by Amura
SynGenicsacquired by Sosei
Ranierprivate
Matrix Therapeutics—

Co-investors across Fund I Merlin Biosciences, Temasek Capital, Friends Ivory & Sime, Genechem Management, Avlar BioVentures, Innoven Partenaires, and Yorkshire Fund Managers.

04 · Reach